[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366423-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366423-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","revolutionizing-cervical-cancer-treatment-single-cell-sequencing-of-tspan1-tumor-epcs-and-immune-checkpoints-to-assess-drug-sensitivity-and-optimize-therapy","Revolutionizing cervical cancer treatment - single-cell sequencing of TSPAN1+ tumor EPCs and immune checkpoints - to assess drug sensitivity and optimize therapy","","Revolutionizing cervical cancer treatment by applying multi-omics and single-cell sequencing to map the tumor microenvironment and immune landscape. The study characterizes tumor endothelial progenitor cell (EPC) epithelial profiles, examines immune-escape mechanisms, and links immune-based tumor subtype classification with drug sensitivity. By integrating immune checkpoint features and TSPAN1-positive tumor EPC biology, the work proposes biomarkers for prognosis and targets to refine personalized therapy. The findings support combining immune checkpoint modulation with precise sensitivity analysis to improve outcomes, especially in advanced disease.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/revolutionizing-cervical-cancer-treatment-single-cell-sequencing-of-tspan1-tumor-epcs-and-immune-checkpoints-to-assess-drug-sensitivity-and-optimize-therapy/366423/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/revolutionizing-cervical-cancer-treatment-single-cell-sequencing-of-tspan1-tumor-epcs-and-immune-checkpoints-to-assess-drug-sensitivity-and-optimize-therapy/366423.png","ImageObject",300,407,{"name":42,"@type":43},"supergirl","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary focus of this study on cervical cancer?","Question",{"text":63,"@type":64},"The study mapped the immune landscape and cellular heterogeneity of cervical cancer and evaluated how tumor endothelial progenitor cell (EPC) subtypes relate to drug sensitivity and therapy response.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which techniques and data types were used?",{"text":68,"@type":64},"The research used multi-omics and single-cell sequencing to explore immune interactions, cellular heterogeneity, and drug sensitivity across cervical cancer tumor subtypes.",{"name":70,"@type":61,"acceptedAnswer":71},"What key biomarkers and therapeutic implications were identified?",{"text":72,"@type":64},"TSPAN1 was identified as a key biomarker, and the results suggest combining immune checkpoint modulation with drug sensitivity analysis to optimize personalized treatment strategies, particularly in advanced cervical cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366423,1790194914,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":99,"preview_page_count":33,"preview_urls":145},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","TYPE Original Research PUBLISHED 24 July 2025  \nDOI 10.3389/fimmu.2025.1574174  \nOPEN ACCESS  \nEDITED BY  \nDan Liu,  \nWuhan University, China  \nREVIEWED BY  \nGuichuan Lai,  \nChongqing Medical University, China Qiang Cao,  \nMacau University of Science and Technology, Macao SAR, China  \nBinggang Liu,  \nThe Central Hospital of Yongzhou, China  \n*CORRESPONDENCE  \nPingping Cai  \n [pingpingcai@126.com](pingpingcai@126.com)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 10 February 2025  \nACCEPTED 21 March 2025  \nPUBLISHED 24 July 2025  \nCITATION  \nLi Y, Lin Z, Lin G, Zhao Z, Xiahou Z and Cai P (2025) Revolutionizing cervical cancer treatment: single-cell sequencing of TSPAN1+ tumor EPCs and immune checkpoints to assess drug sensitivity and optimize therapy. Front. Immunol. 16:1574174 .  \ndoi: 10.3389/fimmu.2025.1574174  \nCOPYRIGHT  \n© 2025 Li, Lin, Lin, Zhao, Xiahou and Cai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nRevolutionizing cervical cancer treatment: single-cell sequencing of TSPAN1+ tumor EPCs and immune checkpoints to assess drug sensitivity and optimize therapy  \nYumeng Li 1†, Zhiheng Lin 2†, Guangyao Lin 2†, Zhijie Zhao 3, Zhikai Xiahou 4 and Pingping Cai 5*  \n1College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China, 2 Department of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, 3 Department of Plastic and Reconstructive Surgery, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 4China Institute of Sport and Health Science, Beijing Sport University, Beijing, China, 5 Department of Traditional Chinese Medicine, Shandong Provincial Hospital Afﬁliated to Shandong First Medical University, Jinan, China  \nBackground: Cervical cancer’s tumor microenvironment (TME) was composed of a diverse array of immune cells that signiﬁcantly inﬂuence tumor progression and response to treatment. Recent advancements in multi-omics and single-cell sequencing had provided valuable insights into the cellular heterogeneity and immune landscape of the TME, revealing critical interactions that shape tumor behavior and therapy outcomes.  \nMethod: This study used multi-omics and single-cell sequencing to explore the immune landscape, cellular heterogeneity, and drug sensitivity in cervical cancer, focused on tumor subtypes and their interactions with immune cells, and aimed to understand therapy responses.  \nResults: The research presented a thorough single-cell analysis of cervical cancer, identiﬁed distinct tumor epithelial cell (EPC) subtypes, and explored their roles in tumor progression, immune evasion, and therapeutic response. It underscored the potential of tumor EPCs as valuable biomarkers for prognosis and as targets for personalized treatment approaches.  \nConclusion: The immune landscape of cervical cancer and its interaction with tumor endothelial progenitor cells played crucial roles in determining the tumor’s progression and response to therapy. The classiﬁcation of tumor subtypes based on immune characteristics and drug sensitivity was critical for personalized  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \ntreatment. The identiﬁcation of TSPAN1 as key biomarkers provided insight into tumor biology and potential therapeutic targets. Our ﬁndings emphasized the need for combining immune checkpoint modulation with precise drug sensitivity analysis to optimize treatment strategies, particularly in advanced cervical cancer.  ","cbCailEgALhQnO6a","https://ap.wps.com/l/cbCailEgALhQnO6a","pdf",31410650,24,"English","# Background\n## Method\n## Results\n## Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What was the primary focus of this study on cervical cancer?\",\"answer\":\"The study mapped the immune landscape and cellular heterogeneity of cervical cancer and evaluated how tumor endothelial progenitor cell (EPC) subtypes relate to drug sensitivity and therapy response.\"},{\"question\":\"Which techniques and data types were used?\",\"answer\":\"The research used multi-omics and single-cell sequencing to explore immune interactions, cellular heterogeneity, and drug sensitivity across cervical cancer tumor subtypes.\"},{\"question\":\"What key biomarkers and therapeutic implications were identified?\",\"answer\":\"TSPAN1 was identified as a key biomarker, and the results suggest combining immune checkpoint modulation with drug sensitivity analysis to optimize personalized treatment strategies, particularly in advanced cervical cancer.\"}]","Revolutionizing cervical cancer treatment - single-cell sequencing of TSPAN1+ tumor EPCs and immune checkpoints - to assess drug sensitivity and optimize therapy | PDF",1790165476,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc48d27a9f96eb58d7feebd80c970947.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2965964f22fa9478af74742097344b36.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b7c216fc6bcfcac4a93e55da87c2dc1.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b3bcefd94e857dcbac78fe7de511b22.webp",980,1385]